UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/523,710	02/04/2005	Mark Fulston	P51369	8388
20462 SMITHKLINE	7590 12/26/200' BEECHAM CORPOR	•	EXAMINER	
CORPORATE INTELLECTUAL PROPERTY-US, UW2220			MARX, IRENE	
P. O. BOX 153 KING OF PRU	9 ISSIA, PA 19406-0939		ART UNIT	PAPER NUMBER
	,		1651	
			NOTIFICATION DATE	DELIVERY MODE
			12/26/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

	Application No.	Applicant(s)	
	10/523,710	FULSTON ET AL.	
Office Action Summary	Examiner	Art Unit	
	Irene Marx	1651	
The MAILING DATE of this communication app	pears on the cover sheet w	ith the correspondence address	
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNI 136(a). In no event, however, may a will apply and will expire SIX (6) MOI e, cause the application to become A	CATION. reply be timely filed ITHS from the mailing date of this communication BANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 19 N	lovember 2007.		
,-	s action is non-final.		
3) Since this application is in condition for allowa			S
closed in accordance with the practice under b	Ex parte Quayle, 1935 C.I	D. 11, 453 O.G. 213.	
Disposition of Claims		1	
4) Claim(s) 2-21 is/are pending in the application	1.		
4a) Of the above claim(s) 2-7 is/are withdrawn	from consideration.		
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>8-21</u> is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/c	or election requirement.	•	
Application Papers			
9) The specification is objected to by the Examine	er.		,
10) The drawing(s) filed on is/are: a) acc	cepted or b) objected to	by the Examiner.	
Applicant may not request that any objection to the			
Replacement drawing sheet(s) including the correct			(d).
11) The oath or declaration is objected to by the E	xaminer. Note the attache	d Office Action of form P10-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
a) All b) Some * c) None of:		•	
1. Certified copies of the priority document			
2. Certified copies of the priority documen			
3. Copies of the certified copies of the price		received in this National Stage	
application from the International Burea * See the attached detailed Office action for a list		received	
See the attached detailed Office action for a list	t of the certified copies no	received.	
	•		
Attachment(s)		Summer (DTO 442)	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No	Summary (PTO-413) (s)/Mail Date	•
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Other:	Informal Patent Application	

10/523,710 Art Unit: 1651

DETAILED ACTION

The amendment filed 11/19/07 is acknowledged. Claims 8-21 are being considered on the merits.

Claims 2-7 are withdrawn from consideration as directed to a non-elected invention.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 12 and 19-21 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No basis or support is found in the present specification for "about 20 psi". The as-filed specification is directed to "pressure (20 psi)".

No basis or support is found in the present specification for the recited yields of ansamitocin by merely using the process outlined in claim 8. The yields are the results of many purification and concentration steps. In addition, while a yield of approximately 92% is outlined in [0027], this yield pertains to "[Overall P-3 yield approximately 92%.]". However, from the context of claim 19 the basis of this yield cannot be determined. It is 92% of the whole broth, for example? In addition, a yield of "98%" or of "greater than 98%" is not found in the instant specification.

Therefore, this material constitutes new matter and should be deleted.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number:

10/523,710 Art Unit: 1651

Claims 8-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 8 is vague, indefinite and confusing in the recitation of "toluene extract from whole broth", since there is no indication of a source for "whole broth" such as a fermentation step. Is the whole broth to be extracted with toluene or is a sample obtained from whole broth extracted with toluene?

Claims 8-13 and 19-21 are incomplete in the absence of a recovery step for the product produced.

While there is no specific rule or statutory requirement which specifically addresses the need for a recovery step in a process of preparing a composition, it is clear from the record and would be expected from conventional preparation processes that the product must be isolated or recovered. Thus, the claims fail to particularly point out and distinctly claim the "complete" process since the recovery step is missing from the claims. The metes and bounds of the claimed process are therefore not clearly established or delineated.

Claims 19-21 fail to find proper antecedent basis in claim 8 for "yield". The sole step in claim 8 is "contacting" with silica gel.

Claim 11 lacks proper antecedent basis for "the silica column" in claim 8 on which it ultimately depends.

Claim 14 is confusing and vague in that it is unclear what is "pooled" upon eluting.

Claims 15 and 16 are confusing in the recitation of "dissolving" and "redissolved". Is a drying step omitted or are these terms inconsistent as pertaining to the same process?

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this

10/523,710 Art Unit: 1651

subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 8-10, 13-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Fulston (US 20030157669).

The claims are directed to a process of capturing ansamitocin by contacting with silica gel a toluene extract obtained from whole broth.

Fulston discloses a process of capturing ansamitocin by contacting with silica gel a toluene extract obtained from whole broth. See, e.g., Examples 1-4

Claims 11 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fulson taken with Terfloth (US 20020156274).

Fulston discloses a process of capturing ansamitocin by contacting with silica gel a toluene extract obtained from whole broth. See, e.g., Examples 1-4. The reference differs from the claimed invention in that the use of pressure is not explicitly disclosed. However, Terfloth adequately demonstrates that it was old and well known at the time the claimed invention was made to apply pressure to silica columns to expedite purification. See, e.g., col. 3, lines 1-5.

Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was made to modify the process of Fulston of capturing ansamitocin by applying pressure to the silica column as suggested by the teachings of Terfloth for the expected

Application/Control Number:

10/523,710 Art Unit: 1651

benefit of maximizing the efficiency of the purification of useful antibiotics such as ansamitocin using silica gel chromatography.

Thus, the claimed invention as a whole was clearly *prima facie* obvious, especially in the absence of evidence to the contrary.

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (571) 272-0919. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Irene Marx
Primary Examiner
Art Unit 1651